Armis Advisers LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Armis Advisers LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 755 shares of the company's stock, valued at approximately $583,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Chokshi & Queen Wealth Advisors Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $741,000. Garde Capital Inc. lifted its holdings in shares of Eli Lilly and Company by 22.7% in the fourth quarter. Garde Capital Inc. now owns 1,107 shares of the company's stock valued at $855,000 after buying an additional 205 shares during the period. Wilkins Miller Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $421,000. Liberty Square Wealth Partners LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $594,000. Finally, Great Valley Advisor Group Inc. lifted its holdings in shares of Eli Lilly and Company by 7.2% in the fourth quarter. Great Valley Advisor Group Inc. now owns 24,756 shares of the company's stock valued at $19,111,000 after buying an additional 1,662 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on LLY shares. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. UBS Group cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Citigroup reduced their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Finally, Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Stock Down 0.9%

Shares of NYSE LLY traded down $6.63 during mid-day trading on Wednesday, reaching $718.59. 2,929,417 shares of the company traded hands, compared to its average volume of 3,620,321. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $681.03 billion, a PE ratio of 61.37, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company's fifty day moving average is $784.45 and its two-hundred day moving average is $801.86. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.58 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.83%. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.